Trial Review

The ANZCTR website will be unavailable from 1pm until 3pm (AEDT) on Wednesday the 30th of October for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
ACTRN12617001144303
Ethics application status
Approved
Date submitted
3/08/2017
Date registered
7/08/2017
Date last updated
21/07/2024
Date data sharing statement initially provided
21/07/2024
Type of registration
Prospectively registered

Titles & IDs
Public title
Comparative assessment of the absorption of a generic formulation of ferrous sulfate controlled release tablet against the innovator ferrous sulfate controlled release tablet conducted under fasting conditions with diet control in healthy male volunteers
Scientific title
A single dose, randomized, blinded, bioequivalence study of a test formulation of ferrous sulfate controlled release tablet in a 2 way crossover comparison against the innovator ferrous sulfate controlled release tablet conducted under fasting conditions with diet control in healthy male volunteers
Secondary ID [1] 292584 0
None
Universal Trial Number (UTN)
U1111-1199-1882
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Iron deficiency.

Although this study is being conducted in healthy volunteers who are not being treated for the condition to which the medicine is used, ferrous sulfate is an iron supplement indicated for the prevention and treatment of iron deficiency. 304255 0
Condition category
Condition code
Blood 303607 303607 0 0
Anaemia
Diet and Nutrition 303619 303619 0 0
Other diet and nutrition disorders

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Single dose, crossover study design whereby each participant receives the test formulation of ferrous sulfate (1 x 325mg) on one occasion and the innovator formulation of ferrous sulfate (1 x 325mg) on one occasion with each dose seperated by a one week washout period. The intervention for this trial is the test formulation of ferrous sulfate.

No water is allowed for 1 hour prior to dosing until 1 hour after dosing (except for the water consumed with the dose).
Participants are required not to eat for 10 hours before receiving each dose and to fast for approximately 4 hours after receiving each dose. Bathroom visits will be supervised to ensure no unauthorised water or food intake and for personal safety. Participants will be confined at the Clinical Site for 10 hours prior to dosing to ensure compliance and will be monitored for 24 hours after dosing.

Standard low iron and low fat meals will be consumed at the Clinical Site with no additional food intake allowed. The meal plan has been designed by a Nutritionist with daily iron content approximately 7mg and fat content approximately 16-21% of total energy per day. Alcohol breath testing will be performed upon each participant reporting to the Clinical Site 10 hours prior to dosing.

Pre and post study laboratory tests will be completed to assess the health of participants along with HIV, Hepatitis and drugs of abuse testing.

Each dose will be taken orally with 240 ml of water at ambient temperature. Medication must be swallowed whole and a mouth check will be conducted to ensure the medication has been taken as directed.
Intervention code [1] 298790 0
Treatment: Drugs
Comparator / control treatment
Single dose, crossover study design whereby each participant receives the test formulation of ferrous sulfate (1 x 325mg) on one occasion and the innovator formulation of ferrous sulfate (1 x 325mg) on one occasion with each dose seperated by a one week washout period. The comparator/control for this trial is the innovator formulation of ferrous sulfate.
Control group
Active

Outcomes
Primary outcome [1] 302960 0
To compare the bioavailability of ferrous sulfate (as summarised by Cmax and AUC) for the formulation. All plasma samples will be assayed for ferrous sulfate using one fully validated colorimetric method. Validation will be conducted to comply with EU and FDA guidelines.
Timepoint [1] 302960 0
-2, -0.5, 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14, 16, 20, 24 and 36 hours post dosing
Secondary outcome [1] 337566 0
Time to maximum peak concentration (Tmax) will be determined by plasma sample analysis. Tmax will be the time where the maximum concentration occurred in the sample points.
Timepoint [1] 337566 0
-2, -0.5, 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14, 16, 20, 24 and 36 hours post dosing

Eligibility
Key inclusion criteria
Healthy males
Aged between 18 and 55
Non-smoker
BMI between 18.5 and 30 inclusive
Normal, healthy individuals as determined by medical history, physical examination, ECG, blood pressure and laboratory tests
Able to provide written informed consent
Minimum age
18 Years
Maximum age
55 Years
Sex
Males
Can healthy volunteers participate?
Yes
Key exclusion criteria
Females
Any history of recent recurrent attacks of bronchitis, asthma, migraine headaches
Concomitant drug therapy of any kind
Sensitivity to ferrous sulfate or any other similar class of medicines, or the excipients of ferrous sulfate
History of any conditions that might interfere with the absorption, distribution, metabolism or excretion of the drug
Smoker (anyone who has smoked in the last 6 months)
History of alcohol or drug abuse or dependency
Participation in a drug study within 60 days of the start of the study or donated blood in the 60 days preceding the study.
Volunteers for whom the Clinical Investigator believes, for any reason, that participation would not be an acceptable risk

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
All formulations will be labelled as Formulation A and B. The identification of each treatment will only be known to the Managing Director, the Section Head - Trials and Regulatory Affairs. or their delegates. The Trial Physician and Principal Investigator are completely blinded and do not know what treatments are allocated to each subject who has been deemed eligible for participation. Allocation concealment to each formulation is completed by central randomisation by computer.
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Each participant will be identified by a 3 digit screening number and a 2 digit subject number. The screening number will be issued once the participant has given written consent to participate in the study and the two digit subject number (randomisation number) after acceptance into the study. Allocation of the subject number is completed by simple randomisation using a randomisation table created by computer software.
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Intervention assignment
Crossover
Other design features
Phase
Phase 1
Type of endpoint/s
Bio-equivalence
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Date of first participant enrolment
Anticipated
10/08/2017
Actual
26/08/2017
Date of last participant enrolment
Anticipated
Actual
26/08/2017
Date of last data collection
Anticipated
Actual
3/09/2017
Sample size
Target
24
Accrual to date
Final
23
Recruitment outside Australia
Country [1] 9122 0
New Zealand
State/province [1] 9122 0
Otago

Funding & Sponsors
Funding source category [1] 297160 0
Commercial sector/Industry
Name [1] 297160 0
Ferromedica Pty Ltd
Country [1] 297160 0
Australia
Primary sponsor type
Commercial sector/Industry
Name
Zenith Technology Corporation Limited
Address
156 Frederick Street
North Dunedin 9016
Country
New Zealand
Secondary sponsor category [1] 296179 0
None
Name [1] 296179 0
Address [1] 296179 0
Country [1] 296179 0

Ethics approval
Ethics application status
Approved
Ethics committee name [1] 298328 0
Northern B Health and Disability Ethics Committee
Ethics committee address [1] 298328 0
Ethics committee country [1] 298328 0
New Zealand
Date submitted for ethics approval [1] 298328 0
19/07/2017
Approval date [1] 298328 0
01/08/2017
Ethics approval number [1] 298328 0
17/NTB/146

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 76734 0
Dr Noelyn Hung
Address 76734 0
Zenith Technology Corporation Limited
156 Frederick Street (PO Box 1777)
Dunedin 9016
Country 76734 0
New Zealand
Phone 76734 0
+6434779669
Fax 76734 0
+6434779605
Email 76734 0
[email protected]
Contact person for public queries
Name 76735 0
Linda Folland
Address 76735 0
Zenith Technology Corporation Limited
156 Frederick Street (PO Box 1777)
Dunedin 9016
Country 76735 0
New Zealand
Phone 76735 0
+6434779669
Fax 76735 0
+6434779605
Email 76735 0
[email protected]
Contact person for scientific queries
Name 76736 0
Tak Hung
Address 76736 0
Zenith Technology Corporation Limited
156 Frederick Street (PO Box 1777)
Dunedin 9016
Country 76736 0
New Zealand
Phone 76736 0
+6434779669
Fax 76736 0
+6434779605
Email 76736 0
[email protected]

Data sharing statement
Will individual participant data (IPD) for this trial be available (including data dictionaries)?
No
No/undecided IPD sharing reason/comment
All data will be compiled into a final report that is the property of the sponsor company. All participant data will be provided in summary format and result of the study only will be reported.


What supporting documents are/will be available?

No Supporting Document Provided



Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
No additional documents have been identified.